259 related articles for article (PubMed ID: 31712395)
1. Selective PRMT5 Inhibitors Suppress Human CD8
Strobl CD; Schaffer S; Haug T; Völkl S; Peter K; Singer K; Böttcher M; Mougiakakos D; Mackensen A; Aigner M
Mol Cancer Ther; 2020 Feb; 19(2):409-419. PubMed ID: 31712395
[TBL] [Abstract][Full Text] [Related]
2. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
Kryukov GV; Wilson FH; Ruth JR; Paulk J; Tsherniak A; Marlow SE; Vazquez F; Weir BA; Fitzgerald ME; Tanaka M; Bielski CM; Scott JM; Dennis C; Cowley GS; Boehm JS; Root DE; Golub TR; Clish CB; Bradner JE; Hahn WC; Garraway LA
Science; 2016 Mar; 351(6278):1214-8. PubMed ID: 26912360
[TBL] [Abstract][Full Text] [Related]
3. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
Mavrakis KJ; McDonald ER; Schlabach MR; Billy E; Hoffman GR; deWeck A; Ruddy DA; Venkatesan K; Yu J; McAllister G; Stump M; deBeaumont R; Ho S; Yue Y; Liu Y; Yan-Neale Y; Yang G; Lin F; Yin H; Gao H; Kipp DR; Zhao S; McNamara JT; Sprague ER; Zheng B; Lin Y; Cho YS; Gu J; Crawford K; Ciccone D; Vitari AC; Lai A; Capka V; Hurov K; Porter JA; Tallarico J; Mickanin C; Lees E; Pagliarini R; Keen N; Schmelzle T; Hofmann F; Stegmeier F; Sellers WR
Science; 2016 Mar; 351(6278):1208-13. PubMed ID: 26912361
[TBL] [Abstract][Full Text] [Related]
4. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
Marjon K; Cameron MJ; Quang P; Clasquin MF; Mandley E; Kunii K; McVay M; Choe S; Kernytsky A; Gross S; Konteatis Z; Murtie J; Blake ML; Travins J; Dorsch M; Biller SA; Marks KM
Cell Rep; 2016 Apr; 15(3):574-587. PubMed ID: 27068473
[TBL] [Abstract][Full Text] [Related]
5. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine.
Barekatain Y; Ackroyd JJ; Yan VC; Khadka S; Wang L; Chen KC; Poral AH; Tran T; Georgiou DK; Arthur K; Lin YH; Satani N; Ballato ES; Behr EI; deCarvalho AC; Verhaak RGW; de Groot J; Huse JT; Asara JM; Kalluri R; Muller FL
Nat Commun; 2021 Jul; 12(1):4228. PubMed ID: 34244484
[TBL] [Abstract][Full Text] [Related]
6. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
7. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition.
Bedard GT; Gilaj N; Peregrina K; Brew I; Tosti E; Shaffer K; Tyler PC; Edelmann W; Augenlicht LH; Schramm VL
J Biol Chem; 2024 Jan; 300(1):105492. PubMed ID: 38000655
[TBL] [Abstract][Full Text] [Related]
8. The Oncometabolite 5'-Deoxy-5'-Methylthioadenosine Blocks Multiple Signaling Pathways of NK Cell Activation.
Jacobs B; Schlögl S; Strobl CD; Völkl S; Stoll A; Mougiakakos D; Malmberg KJ; Mackensen A; Aigner M
Front Immunol; 2020; 11():2128. PubMed ID: 33123121
[TBL] [Abstract][Full Text] [Related]
9. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of
Smith CR; Aranda R; Bobinski TP; Briere DM; Burns AC; Christensen JG; Clarine J; Engstrom LD; Gunn RJ; Ivetac A; Jean-Baptiste R; Ketcham JM; Kobayashi M; Kuehler J; Kulyk S; Lawson JD; Moya K; Olson P; Rahbaek L; Thomas NC; Wang X; Waters LM; Marx MA
J Med Chem; 2022 Feb; 65(3):1749-1766. PubMed ID: 35041419
[TBL] [Abstract][Full Text] [Related]
10. PRMT1 loss sensitizes cells to PRMT5 inhibition.
Gao G; Zhang L; Villarreal OD; He W; Su D; Bedford E; Moh P; Shen J; Shi X; Bedford MT; Xu H
Nucleic Acids Res; 2019 Jun; 47(10):5038-5048. PubMed ID: 30916320
[TBL] [Abstract][Full Text] [Related]
11. PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach.
Barbarino M; Cesari D; Bottaro M; Luzzi L; Namagerdi A; Bertolino FM; Bellan C; Proietti F; Somma P; Micheli M; de Santi MM; Guazzo R; Mutti L; Pirtoli L; Paladini P; Indovina P; Giordano A
J Cell Mol Med; 2020 May; 24(10):5565-5577. PubMed ID: 32301278
[TBL] [Abstract][Full Text] [Related]
12. Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth.
Zhang S; Ma Y; Hu X; Zheng Y; Chen X
J Cell Mol Med; 2019 Feb; 23(2):1333-1342. PubMed ID: 30461193
[TBL] [Abstract][Full Text] [Related]
13. Protein Arginine Methyltransferase 5 Promotes the Migration of AML Cells by Regulating the Expression of Leukocyte Immunoglobulin-Like Receptor B4.
Zhao L; Cheng B; Xiong J; Ma D; Liu X; Wang L; Zhang X; Wang J
Biomed Res Int; 2021; 2021():7329072. PubMed ID: 34712735
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5'-deoxy-5'-methylthioadenosine (MTA).
Kirovski G; Stevens AP; Czech B; Dettmer K; Weiss TS; Wild P; Hartmann A; Bosserhoff AK; Oefner PJ; Hellerbrand C
Am J Pathol; 2011 Mar; 178(3):1145-52. PubMed ID: 21356366
[TBL] [Abstract][Full Text] [Related]
15. Extracellular 5'-methylthioadenosine inhibits intracellular symmetric dimethylarginine protein methylation of FUSE-binding proteins.
Tang B; Lee HO; Gupta S; Wang L; Kurimchak AM; Duncan JS; Kruger WD
J Biol Chem; 2022 Sep; 298(9):102367. PubMed ID: 35963436
[TBL] [Abstract][Full Text] [Related]
16. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
[TBL] [Abstract][Full Text] [Related]
17. Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with
Cottrell KM; Briggs KJ; Whittington DA; Jahic H; Ali JA; Davis CB; Gong S; Gotur D; Gu L; McCarren P; Tonini MR; Tsai A; Wilker EW; Yuan H; Zhang M; Zhang W; Huang A; Maxwell JP
J Med Chem; 2024 Apr; 67(8):6064-6080. PubMed ID: 38595098
[TBL] [Abstract][Full Text] [Related]
18. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
Zhu F; Guo H; Bates PD; Zhang S; Zhang H; Nomie KJ; Li Y; Lu L; Seibold KR; Wang F; Rumball I; Cameron H; Hoang NM; Yang DT; Xu W; Zhang L; Wang M; Capitini CM; Rui L
Leukemia; 2019 Dec; 33(12):2898-2911. PubMed ID: 31123343
[TBL] [Abstract][Full Text] [Related]
19. MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.
Engstrom LD; Aranda R; Waters L; Moya K; Bowcut V; Vegar L; Trinh D; Hebbert A; Smith CR; Kulyk S; Lawson JD; He L; Hover LD; Fernandez-Banet J; Hallin J; Vanderpool D; Briere DM; Blaj A; Marx MA; Rodon J; Offin M; Arbour KC; Johnson ML; Kwiatkowski DJ; Jänne PA; Haddox CL; Papadopoulos KP; Henry JT; Leventakos K; Christensen JG; Shazer R; Olson P
Cancer Discov; 2023 Nov; 13(11):2412-2431. PubMed ID: 37552839
[TBL] [Abstract][Full Text] [Related]
20. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.
Gullà A; Hideshima T; Bianchi G; Fulciniti M; Kemal Samur M; Qi J; Tai YT; Harada T; Morelli E; Amodio N; Carrasco R; Tagliaferri P; Munshi NC; Tassone P; Anderson KC
Leukemia; 2018 Apr; 32(4):996-1002. PubMed ID: 29158558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
